11,669 results match your criteria Acute Promyelocytic Leukemia


Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.

Ann Hematol 2022 May 20. Epub 2022 May 20.

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

The optimal follow-up care for relapse detection in acute myeloid leukemia (AML) patients in first remission after consolidation therapy with intensive chemotherapy is not established. In this retrospective study, we evaluate the diagnostic value of an intensive relapse surveillance strategy by regular bone marrow aspirations (BMA) in these patients. We identified 86 patients with newly diagnosed non-promyelocytic AML who had reached complete remission (CR) after intensive induction and consolidation chemotherapy between 2007 and 2019. Read More

View Article and Full-Text PDF

Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.

PLoS One 2022 20;17(5):e0268835. Epub 2022 May 20.

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Ibaraki, Japan.

Promyelocytic leukemia (PML) proteins are involved in the pathogenesis of acute promyelocytic leukemia (APL). Trivalent arsenic (As3+) is known to cure APL by binding to cysteine residues of PML and enhance the degradation of PML-retinoic acid receptor α (RARα), a t(15;17) gene translocation product in APL cells, and restore PML-nuclear bodies (NBs). The size, number, and shape of PML-NBs vary among cell types and during cell division. Read More

View Article and Full-Text PDF

G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells.

Cancer Cell Int 2022 May 19;22(1):195. Epub 2022 May 19.

Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL) patients, but it fails to show satisfactory efficacy in other acute myeloid leukemia (AML) patients with non-APL subtypes. Different from the APL cells, most non-APL AML cells express low levels of the ATO transporter Aquaporin-9 (AQP9) protein, making them less sensitive to ATO treatment. Recently, we found that granulocyte colony stimulating factor (G-CSF) can upregulate the expression of AQP9. Read More

View Article and Full-Text PDF

Various types of electrochemical biosensors for leukemia detection and therapeutic approaches.

Anal Biochem 2022 May 16:114736. Epub 2022 May 16.

Department of Anatomy, Histology Forensic Medicine, Sapienza University of Rome, Rome, Italy.

Leukemia often initiates following dysfunctions in hematopoietic stem cells lineages. Various types of leukemia, including acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), and human T-cell leukemia/lymphoma virus type 1 (HTLV-1) can thus call for different diagnosis and treatment options. One of the most important subjects in leukemia is the early detection of the disease for effective therapeutic purposes. Read More

View Article and Full-Text PDF

Thrombocytopenia: the good, the bad and the ugly.

Clin Med (Lond) 2022 May;22(3):214-217

University Hospitals Sussex NHS Foundation Trust, Brighton, UK and Brighton and Sussex Medical School, Falmer, UK.

New thrombocytopenia may be associated with a variety of conditions and diagnosis can be challenging. Presentation can vary from life-threatening bleeding or thrombosis to an incidental finding in an asymptomatic patient. New thrombocytopenia requires urgent investigation. Read More

View Article and Full-Text PDF

Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era.

Leuk Res Rep 2022 4;17:100320. Epub 2022 May 4.

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Acute promyelocytic leukemia (APL) is a unique leukemia that is characterized by the fusion. This fusion is often detected by conventional karyotype and fluorescence in situ hybridization (FISH); however, rare cases are cryptic and require molecular techniques to identify the fusion. Furthermore, as the incidence of these cases is rare, analysis by a targeted next-generation sequencing (NGS) panel of myeloid associated genes has never been reported. Read More

View Article and Full-Text PDF

The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements Epigenetic Modification.

Front Pharmacol 2022 27;13:876076. Epub 2022 Apr 27.

School of Pharmacy, Weifang Medical University, Weifang, China.

Acute leukemia (AL) is characterized by excessive proliferation and impaired differentiation of leukemic cells. AL includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Previous studies have demonstrated that about 10% of AML and 22% of ALL are mixed lineage leukemia gene rearrangements (MLLr) leukemia. Read More

View Article and Full-Text PDF

Anticancer Activities of Lour.: A Systematic Review.

Front Pharmacol 2022 27;13:875016. Epub 2022 Apr 27.

Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkoknoi, Thailand.

Cancers are a potential cause of death worldwide and represent a massive burden for healthcare systems. Treating cancers requires substantial resources, including skilled personnel, medications, instruments, and funds. Thus, developing cancer prevention and treatment measures is necessary for healthcare personnel and patients alike. Read More

View Article and Full-Text PDF

Arsenic in Drinking Water and Incidences of Leukemia and Lymphoma: Implication for Its Dural Effects in Carcinogenicity.

Front Public Health 2022 29;10:863882. Epub 2022 Apr 29.

Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Arsenic in drinking water has been recognized as carcinogenic to humans and can cause solid cancers of lung, urinary bladder, and skin. Positive associations have also been reported between arsenic ingestion and cancers of kidney, liver and prostate. Nevertheless, arsenic trioxide has been used successfully in the treatment of acute promyelocytic leukemia. Read More

View Article and Full-Text PDF

Responses of promyelocytic leukemia HL60 cells as an inflammatory cell lineage model to silica microparticles used to coat blood collection tubes.

Int J Implant Dent 2022 May 14;8(1):24. Epub 2022 May 14.

Division of Oral Bioengineering, Institute of Medicine and Dentistry, Niigata University, Niigata, Japan.

Background: The preparation of platelet-rich fibrin (PRF) requires glass blood collection tubes, and thus, the shortage or unavailability of such tubes has driven clinicians to search for suitable substitutes, such as silica-coated plastic tubes. However, we have previously demonstrated the cytotoxicity of silica microparticles (MPs) used in plastic tubes to cultured human periosteal cells. To further establish the effects of silica MPs on inflammation, we examined silica MP-induced changes in a human promyelocytic cell model in vitro. Read More

View Article and Full-Text PDF

Mast cell neoplasm: a challenging pathological diagnosis.

Hum Pathol 2022 May 9. Epub 2022 May 9.

Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil; Laboratory of Investigative Pathology, CIPED, University of Campinas (Unicamp), Campinas, São Paulo, Brazil; Anatomic Pathology D'Or Hospitals Network, São Paulo, Brazil; Multipat Laboratory of Pathology, Campinas, São Paulo, Brazil.

Systemic mastocytosis (SM) is a myeloid neoplasm characterized by abnormal growth and accumulation of neoplastic mast cells in at least one extracutaneous site. Clinical presentation and course are variable, most patients developing an indolent disease and some, an aggressive/leukemic form. Because of its rarity, most physicians are unfamiliar with this disease and do not readily diagnose it. Read More

View Article and Full-Text PDF

Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.

Oncogene 2022 May 11. Epub 2022 May 11.

Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.

View Article and Full-Text PDF

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor alpha with the PML/RAR alpha fusion protein on super-enhancers.

Haematologica 2022 May 12. Epub 2022 May 12.

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; CNRS-LIA Hematology and Cancer, Sino-French Research Center for Life Sciences and Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai.

Patients with newly diagnosed acute promyelocytic leukemia (APL) are often obese or overweight, accompanied by metabolic disorders, such as dyslipidemia. However, the link between dyslipidemia and leukemia is obscure. Here, we conducted a retrospective study containing 1,412 cases (319 newly diagnosed APL patients, 393 newly diagnosed non-APL acute myeloid leukemia patients, and 700 non-tumor controls) and found that APL patients had higher triglyceride levels than non-APL and control groups. Read More

View Article and Full-Text PDF

A short report of novel gene in resembling acute promyelocytic leukemia.

Hematology 2022 Dec;27(1):518-522

State Key Laboratory of Experimental Hematology, Tianjin, People's Republic of China.

Background: Resembling acute promyelocytic leukemia (APL) is a unique subtype of APL who sharing clinical, morphological, and immunophenotypic features with typical APL, but lacking evidence of fusion gene and usually insensitive to arsenic trioxide (ATO) and all-trans retinoic acid (ATRA). For years, rearrangement were found in resembling APL continually. The confirmed partner genes of rearrangement included , , , , and . Read More

View Article and Full-Text PDF
December 2022

A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis.

Eur J Intern Med 2022 May 5. Epub 2022 May 5.

The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, 1, Efron St, Haifa 3109601, Israel; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8, Ha'Aliya Street, Haifa 3109601, Israel. Electronic address:

Background: Catheter-related thrombosis (CRT) is a common complication in cancer patients, that may lead to chemotherapy deferral, elevated risk for systemic infections and pulmonary embolism. This study aimed to assess CRT incidence and risk factors in newly-diagnosed acute myeloid leukemia (AML) patients and create predictive models potentially allowing to decrease CRT occurrence in this population.

Methods: This retrospective single-center analysis included all AML patients treated at the Rambam Health Care Campus between 2006 and 2019. Read More

View Article and Full-Text PDF

Do high-mobility group box 1 gene polymorphisms affect the incidence of differentiation syndrome in acute promyelocytic leukemia?

Mol Biol Rep 2022 May 8. Epub 2022 May 8.

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Background: Differentiation syndrome (DS) is an inflammatory complication seen in some patients with acute promyelocytic leukemia (APL) undergoing differentiation therapy with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). It is unknown how DS occurs, but it is believed that it is caused by inflammatory cytokines release from differentiating leukemic cells. High mobility group box-1 (HMGB1) is a DNA-binding protein that acts as a cytokine outside of cells and may play a role in inflammation. Read More

View Article and Full-Text PDF

Arsenic trioxide induces proteasome dependent TBLR1-RARα degradation to improve leukemia eradication through cell differentiation enhancement.

J Cancer 2022 18;13(7):2301-2311. Epub 2022 Apr 18.

Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang, China, 310016.

Background: Acute promyelocytic leukemia (APL) mainly harbors PML-RARα fusion gene, which is sensitive to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) treatment. However, APL harboring other RARα fusion genes exhibit different drug sensitivity. Here, we investigated the role and mechanism of TBLR1-RARα, a rare RARα fusion gene, on ATO treatment in leukemia cells. Read More

View Article and Full-Text PDF

CD44-fibrinogen binding promotes bleeding in acute promyelocytic leukemia by in situ fibrin(ogen) deposition.

Blood Adv 2022 May 5. Epub 2022 May 5.

Harvard Medical School, United States.

Early haemorrhagic death is still the main obstacle for the successful treatment of acute promyelocytic leukaemia (APL). However, the mechanisms underlying haemostatic perturbations in APL have not been fully elucidated. Here, we report that CD44 on the membrane of APL blasts and NB4 cells ligated bound fibrinogen, resulting in in situ deposition of fibrin and abnormal fibrin distribution. Read More

View Article and Full-Text PDF

Reduced expression of lncRNA DLEU7-AS1 is a novel favorable prognostic factor in acute myeloid leukemia.

Biosci Rep 2022 May;42(5)

Surgery of Traditional Chinese Medicine, Haian Hospital of Traditional Chinese Medicine, Nantong, Jiangsu, People's Republic of China.

The objective of our study was to measure DLEU7-AS1 expression in de novo acute myeloid leukemia (AML) whilst also analyzing its clinical relevance. We used gene expression data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Cancer Cell Line Encyclopedia (CCLE) and Genotype-Tissue Expression project (GTEx) to assess the expression profile of DLEU7-AS1 in pan-cancers, cancer cell lines and normal tissues. Reverse transcription-quantitative PCR was used to measure DLEU7-AS1 expression in bone marrow from 30 normal individuals and 110 patients with de novo AML. Read More

View Article and Full-Text PDF

Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia.

BMC Cancer 2022 May 2;22(1):481. Epub 2022 May 2.

Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan Xi Road, Wenzhou, Zhejiang, 325000, P.R. China.

Background: Acute promyelocytic leukaemia (APL) is a unique subtype of acute myeloid leukaemia (AML) characterized by haematopoietic failure caused by the accumulation of abnormal promyelocytic cells in bone marrow (BM). However, indispensable BM biopsy frequently afflicts patients in leukaemia surveillance, which increases the burden on patients and reduces compliance. This study aimed to explore whether the novel circulating long noncoding RNA LOC100506453 (lnc-LOC) could be a target in diagnosis, assess the treatment response and supervise the minimal residual disease (MRD) of APL, thereby blazing a trail in noninvasive lncRNA biomarkers of APL. Read More

View Article and Full-Text PDF

High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.

Indian J Hematol Blood Transfus 2022 Apr 3;38(2):394-402. Epub 2021 Sep 3.

Department of Hematology and BMT Unit, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi 110085 India.

Management of Acute Promyelocytic Leukemia (APML) has improved drastically after the introduction of ATRA (-trans-retinoic acid) and Arsenic trioxide (ATO). The use of APML-4 protocol has shown its effectiveness in Australian population. We know that high-risk APML represents a subset with poor outcomes. Read More

View Article and Full-Text PDF

Acute Promyelocytic Leukemia with Hyperleukocytosis: Improving Outcomes with Current Therapy.

Indian J Hematol Blood Transfus 2022 Apr 17;38(2):427-428. Epub 2022 Jan 17.

Department of Haematology, All India Institute of Medical Sciences, New Delhi, India.

View Article and Full-Text PDF

Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission.

Front Genet 2022 12;13:821676. Epub 2022 Apr 12.

Department of Molecular Cell Biology, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, Lithuania.

Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For many types of cancer, finding cancer early makes it easier to treat. Identifying prognostic molecular markers and understanding their biology are the first steps toward developing novel diagnostic tools or therapies for patients with AML. Read More

View Article and Full-Text PDF

Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.

Front Oncol 2022 12;12:871590. Epub 2022 Apr 12.

Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.

Acute promyelocytic leukemia (APL) accounts for 10-15% of newly diagnosed acute myeloid leukemias (AML) and is typically caused by the fusion of promyelocytic leukemia with retinoic acid receptor α () gene. The prognosis is excellent, thanks to the all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combination therapy. A small percentage of APLs (around 2%) is caused by atypical transcripts, most of which involve or other members of retinoic acid receptors ( or ). Read More

View Article and Full-Text PDF

Corrigendum to "Autophagy contributes to 4-Amino-2-Trifluoromethyl-Phenyl Retinate-induced differentiation in human acute promyelocytic leukemia NB4 cells" [Toxicology and Applied Pharmacology 319 (2017) 1-11].

Toxicol Appl Pharmacol 2022 Apr 27:116040. Epub 2022 Apr 27.

Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, Anhui Province 230032, China. Electronic address:

View Article and Full-Text PDF

Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells.

Cancer Cell Int 2022 Apr 29;22(1):169. Epub 2022 Apr 29.

Department of Pathology, Tianjin Union Medical Center, Tianjin, 300071, People's Republic of China.

Chondrogenesis is the formation of chondrocytes and cartilage tissues and starts with mesenchymal stem cell (MSC) recruitment and migration, condensation of progenitors, chondrocyte differentiation, and maturation. The chondrogenic differentiation of MSCs depends on co-regulation of many exogenous and endogenous factors including specific microenvironmental signals, non-coding RNAs, physical factors existed in culture condition, etc. Cancer stem cells (CSCs) exhibit self-renewal capacity, pluripotency and cellular plasticity, which have the potential to differentiate into post-mitotic and benign cells. Read More

View Article and Full-Text PDF

Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia.

Front Immunol 2022 11;13:841445. Epub 2022 Apr 11.

Department of Hematology, First Affiliated Hospital of Harbin Medical University, Harbin, China.

The rate of complete remission of acute promyelocytic leukemia (APL) is currently over 90% because of the use of all-trans retinoic acid (ATRA) with arsenic trioxide (ATO). However, hemorrhagic mortality has emerged as the most significant barrier to APL-induced remission. Neutrophils extracellular traps (NETs/ETs) cause vascular leakage by damaging the integrity of endothelial cells. Read More

View Article and Full-Text PDF

Annexin A2: The diversity of pathological effects in tumorigenesis and immune response.

Int J Cancer 2022 Apr 26. Epub 2022 Apr 26.

Department of Internal Medicine, Digestive Disease Section, Yale University, New Haven, Connecticut, USA.

Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial-mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmin, which participates in pathophysiologic processes such as tumor cell invasion and metastasis, bleeding diseases, angiogenesis, inducing the expression of inflammatory factors. Read More

View Article and Full-Text PDF

Epidemiology of de novo acute myeloid leukemia in Kuwait per the 2016-WHO classification.

Med Princ Pract 2022 Apr 25. Epub 2022 Apr 25.

Introduction: Acute myeloid leukemia (AML) is a hematological malignancy that arises from the clonal proliferation of immature myeloid cells. Although the number of AML cases has dramatically increased worldwide, an understanding of its prevalence and incidence in Kuwait is lacking.

Method: This study reports the incidence of AML and patient demographics in the country from 2014 to 2020, according to the 2016 WHO classification of AML. Read More

View Article and Full-Text PDF

Fatal intracranial hemorrhage as the presenting sign of acute promyelocytic leukemia: A case report.

Radiol Case Rep 2022 Jun 12;17(6):2123-2128. Epub 2022 Apr 12.

Department of Neurological Surgery, Wake Forest Baptist Medical Center, Winston Salem, NC, USA.

Intracranial hemorrhage (ICH) can be a devastating medical event with numerous potential etiologies. In young people under age 40, ruptured vascular malformation is the most common cause of ICH. Without critical review of imaging and laboratory findings and clinical suspicion beyond vascular malformation, alternative etiologies of hemorrhage may be overlooked in the younger age group. Read More

View Article and Full-Text PDF